Immunogenicity and safety of a tetravalent recombinant subunit dengue vaccine in adults previously vaccinated with a live attenuated tetravalent dengue vaccine: Results of a phase-I randomized clinical trial

Anna P. Durbin, Kristen K. Pierce, Beth D. Kirkpatrick, Palmtama Grier, Beulah P. Sabundayo, Helen He, Michele Sausser, Amy Falk Russell, Jason Martin, Donna Hyatt, Melissa Cook, Jeffrey R. Sachs, Andrew Wen Tseng Lee, Liman Wang, Beth Ann Coller, Stephen S. Whitehead

Research output: Contribution to journalArticlepeer-review

Abstract

New dengue vaccines are needed to prevent this globally expanding vector-borne disease. The V180 vaccine candidate consists of four recombinant, soluble, dengue virus envelope glycoproteins and has been previously evaluated in two clinical trials for safety and immunogenicity in Flavivirus-naive participants (NCT01477580 and NCT0093642). Here, we report on a randomized, placebo-controlled, double-blind study of the safety and immunogenicity of the V180 vaccine in subjects who have previously received the live attenuated tetravalent vaccine (LATV) developed by the National Institute of Allergy and Infectious Diseases (protocol #V180-002 [CIR-301]). The study was designed to evaluate whether this recombinant subunit vaccine could boost the neutralizing antibody responses induced by dengue LATV. Twenty participants who had previously received one or two doses of dengue LATV were randomized and received a single dose of V180 nonadjuvanted (N = 8), V180 adjuvanted with Alhydrogel™ (aluminum hydroxide gel, Brenntag Biosector, Frederikssund, Denmark) (N = 8), or placebo (N = 4). Immunogenicity was measured using a plaque reduction neutralization test at days 1, 15, 28, and 180 after vaccination. In addition, vaccine safety (solicited and unsolicited adverse events) was assessed using a vaccination report card for 28 days following vaccination, and serious adverse events were captured from the time of informed consent through the final study visit at 6 months after vaccination. The results of the study demonstrate that the V180 vaccine is generally well tolerated and immunogenic in these dengue-seropositive volunteers.

Original languageEnglish (US)
Pages (from-to)855-863
Number of pages9
JournalAmerican Journal of Tropical Medicine and Hygiene
Volume103
Issue number2
DOIs
StatePublished - Aug 2020

ASJC Scopus subject areas

  • Parasitology
  • Virology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Immunogenicity and safety of a tetravalent recombinant subunit dengue vaccine in adults previously vaccinated with a live attenuated tetravalent dengue vaccine: Results of a phase-I randomized clinical trial'. Together they form a unique fingerprint.

Cite this